No Picture
News

BioMarin’s Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020

No Advisory Committee Meeting Currently Planned to Review the ApplicationIf approved, 1st Gene Therapy in U.S. for the Treatment of Any Type of HemophiliaFDA Also Accepts Premarket Approval (PMA) Application for Companion Diagnostic Test, a 1st for a G… […]

No Picture
News

VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder

PH10, a Neurosteroid Nasal Spray, Demonstrated Significant Rapid-Onset Antidepressive Benefit versus Placebo, without Psychological Side Effects or Safety Concerns Often Associated with Ketamine-based Therapy

SOUTH SAN FRANCISCO, Calif., Feb. 20, 202… […]

No Picture
News

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End Financial Results

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2019 financial results after market close on Thursday, February 27, 2020. Rigel … […]

No Picture
News

Invitae Reports $216.8 Million in Annual Revenue Driven by More Than 482,000 Samples in 2019

— Increased annual revenue by approximately 47% and annual volume by nearly 60% year-over-year —- Issued 2020 guidance of more than 725,000 samples accessioned and more than $330 million in revenue, reflecting a more than 50% annual growth in both v… […]

No Picture
News

Protagonist Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference in New York

NEWARK, Calif., Feb. 19, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a corporate overview at the upcoming the SVB Leerink 9th Annu… […]

No Picture
News

VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 /PRNewswire/ — VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet … […]

No Picture
News

Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients

– Onvansertib demonstrates efficacy in Zytiga®-resistant metastatic castration-resistant prostate cancer (mCRPC) across known androgen receptor resistance mechanisms- Onvansertib-induced decreases in circulating tumor cells (CTCs) is a surrogate for ef… […]

No Picture
News

Thermo Fisher Scientific Announces Collaboration to Develop Highly Sensitive Analytical Workflow for Infectious Disease Diagnosis and Patient Monitoring

SAN JOSE, Calif., Feb. 13, 2020 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, and NanoPin Technologies, Inc., the developer of the novel NanoPin diagnostic platform for rapid and quantified results from patient blood… […]